Sign in
Taking people in South KoreaPhase 3

Comparing two weight-loss surgeries for type 2 diabetes in adults

Compares sleeve gastrectomy with bypass against sleeve gastrectomy alone in adults with type 2 diabetes.

Key facts

Who runs it
Seoul National University Bundang Hospital
Where
Seongnam-si, South KoreaSee the site
Trial code
Registry title
Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
Status
Recruiting
Phase
Phase 3
People taking part
130 people, planned
Started
3 Jan 2022
Expected to end
3 Jan 2036
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Duodenojejunal bypass
  • Sleeve gastrectomy
Record updated
27 January 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes and a high body weight whose blood sugar is still poorly controlled. It compares two weight-loss operations.

Age
Over 18 years
Sex
All sexes can join
Disease stage
Type 2 diabetes for 10 years or less, with poor blood sugar control despite treatment. Must use insulin, or have HbA1c 7.0% (53 mmol/mol) or higher while taking diabetes medicine. C-peptide level must be higher than 1.0 ng/mL.
Earlier treatment
No earlier metabolic surgery for type 2 diabetes. No earlier stomach or gut surgery that could affect the result.
Biomarker or test result
BMI 27.5 kg/m2 or higher. C-peptide higher than 1.0 ng/mL. HbA1c 7.0% (53 mmol/mol) or higher if not using insulin.

Main reasons for not taking part

  • Severe acid reflux that is not controlled (LA classification C or more)
  • Earlier metabolic surgery for type 2 diabetes
  • Earlier stomach or gut surgery that may affect the result
  • More than 3 psychiatric drugs because of poorly controlled psychiatric illness
  • Suicide attempt or treatment for alcohol or drug abuse in the last 12 months

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Age over 18 years
  • BMI equal to or greater than 27.5 kg/m2
  • T2DM duration ≤ 10 years
  • Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication
  • C-peptide level higher than 1.0 ng/mL
  • Presence of type 2 diabetes fulfilling the following criteria
  • Consent to not become pregnant for at least 1 year after surgery
  • Willingness to provide voluntary informed consent

Who cannot take part

  • History of previous metabolic surgery for T2DM
  • Treatment for alcohol and drug abuse within the last 12 months
  • History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery
  • Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders
  • Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)
  • Suicidal attempts within the last 12 months
  • Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation)
  • Unsuitability as per the discretion of the researcher

Where in South Korea

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Young Suk ParkTaking people

About the trial

What the trial wants to find out

In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).

Read full original descriptionShow less

This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.

The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group

The 2 groups in the trial

  • SG groupExisting treatment, for comparison

    Patients undergoing sleeve gastrectomy

    Treatment: Sleeve gastrectomy

  • DJB groupTreatment being tested

    Patients undergoing duodenojejunal bypass with sleeve gastrectomy

    Treatment: Duodenojejunal bypass

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial
Plain-language title
Comparing two weight-loss surgeries for type 2 diabetes in adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 January 2022